Cytokinetics Inc Market Cap ($8.62 Billion)
Market Cap & Net Worth: Cytokinetics Inc (CYTK)
Cytokinetics Inc market cap. Cytokinetics Inc (NASDAQ:CYTK) has a market capitalization of $8.62 Billion ($8.62 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2406 globally and #900 in its home market, demonstrating a 1.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytokinetics Inc's stock price $62.99 by its total outstanding shares 139023418 (139.02 Million).
Cytokinetics Inc Market Cap History (2015–2026)
Cytokinetics Inc market cap history from 2015 to 2026. Data shows growth from $1.45 Billion to $8.76 Billion (22.12% CAGR). Check CYTK share price today for real-time trading data and today's change.
Index Memberships
Cytokinetics Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.33% | #53 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.02% | #278 of 3165 |
|
S&P Midcap 400
MID
|
$3.34 Trillion | 0.18% | #151 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.47% | #36 of 263 |
Weight: Cytokinetics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cytokinetics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytokinetics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Cytokinetics Inc (CYTK) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
100.34x
Cytokinetics Inc's market cap is 100.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.69 Billion | $106.41 Million | $16.45 Million | 15.87x | 102.66x |
| 2017 | $1.13 Billion | $13.37 Million | -$127.79 Million | 84.76x | N/A |
| 2018 | $878.63 Million | $31.50 Million | -$106.29 Million | 27.89x | N/A |
| 2019 | $1.48 Billion | $26.87 Million | -$121.69 Million | 54.90x | N/A |
| 2020 | $2.89 Billion | $55.83 Million | -$127.29 Million | 51.75x | N/A |
| 2021 | $6.34 Billion | $70.43 Million | -$215.31 Million | 89.97x | N/A |
| 2022 | $6.37 Billion | $94.59 Million | -$388.95 Million | 67.35x | N/A |
| 2023 | $11.61 Billion | $7.53 Million | -$526.24 Million | 1541.44x | N/A |
| 2024 | $6.54 Billion | $18.47 Million | -$589.53 Million | 353.99x | N/A |
| 2025 | $8.83 Billion | $88.04 Million | -$784.96 Million | 100.34x | N/A |
Competitor Companies of CYTK by Market Capitalization
Companies near Cytokinetics Inc in the global market cap rankings as of October 31, 2026. See Cytokinetics Inc balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Cytokinetics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Cytokinetics Inc (2015–2026)
Market capitalization of Cytokinetics Inc from 2015 to today. Between 2015 and today, Cytokinetics Inc's market cap moved from $1.45 Billion to $ 8.76 Billion, with a yearly change of 22.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.76 Billion | -0.87% |
| 2025 | $8.83 Billion | +35.08% |
| 2024 | $6.54 Billion | -43.66% |
| 2023 | $11.61 Billion | +82.21% |
| 2022 | $6.37 Billion | +0.53% |
| 2021 | $6.34 Billion | +119.35% |
| 2020 | $2.89 Billion | +95.85% |
| 2019 | $1.48 Billion | +67.88% |
| 2018 | $878.63 Million | -22.45% |
| 2017 | $1.13 Billion | -32.92% |
| 2016 | $1.69 Billion | +16.16% |
| 2015 | $1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Cytokinetics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.62 Billion USD |
| MoneyControl | $8.62 Billion USD |
| MarketWatch | $8.62 Billion USD |
| marketcap.company | $8.62 Billion USD |
| Reuters | $8.62 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more